01
Carbon input
Residual industrial carbon and renewable carbon feedstock are inputs in the company-described approach to biochemical manufacture.
Conceptual visualization
CIRCULAR CARBON. PROGRAMMABLE BIOLOGY.
Designer molecules,made sustainably.
Lypo is developing a biotechnology platform to turn renewable carbon into high-performance biochemicals, with biodegradable cosmetic ingredients as a target application.
Discover the possibilities01 — LYPO / CIRCULAR BIOLOGY
OUR PURPOSE
Nature’s potential. Engineered possibilities.
Synthetic biology enables circularity. Our ambition is the sustainable manufacture of bespoke biochemicals, bringing renewable carbon and programmable biology together.
Explore our technologyCarbon inputAI-powered protein designCosmetic ingredients
THE PLATFORM
A new purpose for carbon.
From residual industrial carbon to designed biochemical outputs: explore the concepts behind Lypo’s platform approach.
02
AI-powered protein design
AI-powered protein design and engineering are part of the approach to exploring enzyme designs.
03
High-throughput variant screening
High-throughput screening of enzyme variants helps identify candidates for performance targets. Screening capacity and assay results have not yet been published.
04
Cosmetic ingredient targets
The current target application is high-performance biodegradable cosmetic ingredients with programmable functional properties, in development rather than commercially available.
APPLICATIONS
Designed for performance. Directed towards circularity.
A focused application objective today. A distinct platform ambition for the longer term.
CURRENT TARGET APPLICATION
Cosmetic ingredients
Lypo targets high-performance biodegradable cosmetic ingredients, aiming for control over functional properties. These are development objectives, not commercially available products.
LONG-TERM PLATFORM GOAL
Advanced therapeutics
Advanced therapeutics are a long-term platform ambition, including potential applications for aggressive brain cancer and diabetes. Lower production costs are a goal, not a demonstrated outcome.
Long-term ambition, not a current clinical pipeline. Clinical efficacy, approved treatments and commercially available therapeutic products are not established.
COMPANY UPDATE
15 / 09 / 2026
Part of the 2026 Industrial Biotech Bootcamp cohort.
Lypo was included in the cohort announcement published on 15 September 2026 by Biotech Booster. The programme is organised by Biotech Booster and Planet B.io.
Read the organiser’s announcementLET’S CONNECT
Let’s explore the possibilities.
Connect with Lypo to discuss its platform and potential collaboration.